Rifaximin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Severe Hepatic Impairment
Conditions
Severe Hepatic Impairment
Trial Timeline
Jan 29, 2019 → Feb 2, 2020
NCT ID
NCT03818672About Rifaximin
Rifaximin is a approved stage product being developed by Bausch Health for Severe Hepatic Impairment. The current trial status is terminated. This product is registered under clinical trial identifier NCT03818672. Target conditions include Severe Hepatic Impairment.
What happened to similar drugs?
20 of 20 similar drugs in Severe Hepatic Impairment were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03818672 | Approved | Terminated |
| NCT03462966 | Phase 2 | Terminated |
| NCT01654939 | Approved | Withdrawn |
| NCT01542541 | Pre-clinical | Completed |
| NCT00743912 | Phase 1 | Completed |
| NCT00686920 | Phase 3 | Completed |
| NCT00328380 | Phase 3 | Completed |
| NCT00269412 | Phase 2 | Completed |
| NCT00259155 | Phase 2 | Completed |
| NCT00098384 | Phase 2 | Completed |
Competing Products
20 competing products in Severe Hepatic Impairment